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Abstract
Background: The delivery of ubiquitinated proteins to the proteasome for degradation is a key
step in the regulation of the ubiquitin-proteasome pathway, yet the mechanisms underlying this
step are not understood in detail. The Rad23 family of proteins is known to bind ubiquitinated
proteins through its two ubiquitin-associated (UBA) domains, and may participate in the delivery
of ubiquitinated proteins to the proteasome through docking via the Rad23 ubiquitin-like (UBL)
domain.
Results: In this study, we investigate how the interaction between the UBL and UBA domains may
modulate ubiquitin recognition and the delivery of ubiquitinated proteins to the proteasome by
autoinhibition. We have explored a competitive binding model using specific mutations in the UBL
domain. Disrupting the intramolecular UBL-UBA domain interactions in HHR23A indeed
potentiates ubiquitin-binding. Additionally, the analogous surface on the Rad23 UBL domain
overlaps with that required for interaction with both proteasomes and the ubiquitin ligase Ufd2.
We have found that mutation of residues on this surface affects the ability of Rad23 to deliver
ubiquitinated proteins to the proteasome.
Conclusion: We conclude that the competition of ubiquitin-proteasome pathway components for
surfaces on Rad23 is important for the role of the Rad23 family proteins in proteasomal targeting.
Background
Targeted protein degradation by the ubiquitin-proteas-
ome pathway is a key means of regulating a wide variety
of cellular processes, ranging from cell cycle progression
[1] to antigen presentation [2]. In this pathway, an enzy-
matic cascade covalently attaches ubiquitin to a lysine res-
idue on substrate proteins. The subsequent conjugation of
more ubiquitin moieties, each typically linked through
Lys48 of ubiquitin, results in a polyubiquitin chain that
directs substrate proteins to the proteasome where they
are degraded (reviewed in [3]). The importance of this
proteasome-targeting step was demonstrated by experi-
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ments showing that the artificial localization of proteins
to the proteasome is sufficient to cause their degradation
[4].
Recent work indicates that ubiquitin receptors, which
bind ubiquitin but are not intrinsic subunits of the protea-
some, facilitate the docking of ubiquitinated substrates to
the proteasome [5-8]. The best-studied of these receptors
are the UBL-UBA proteins and include three groups:
Rad23/HHR23A/HHR23B, Dsk2/PLIC1/PLIC2, and
Ddi1. Rad23, for example, has been shown to play a role
in the targeting of the cyclin-dependent kinase inhibitor
Sic1 to the proteasome [5], and Ddi1 mediates degrada-
tion of the Ho endonuclease [9] and of the F-box protein
Ufo1 [10].
Each Rad23 family member has a ubiquitin-like (UBL)
domain that binds proteasomes [11-13] as well as two
ubiquitin-associated (UBA) domains that bind ubiquitin
[14-17]. The structure of HHR23A has been solved by
NMR spectroscopy [18,19], which revealed that the UBL
and UBA domains interact intramolecularly in a highly
dynamic manner, as each UBA domain competes for an
overlapping UBL domain surface [18]. The UBL domain
of HHR23A has also been shown to bind to proteasomal
subunit S5a [12], and notably, the UBL surface bound by
S5a overlaps significantly with that bound by the UBA
domains [18]. As with the UBL domain of HHR23A, the
UBA domains also have multifunctional surfaces: specifi-
cally, the UBL- and ubiquitin-binding surfaces overlap.
The binding of S5a or ubiquitin to HHR23A thus disrupts
the intramolecular UBL-UBA interactions and drives
HHR23A into an open conformation [18,20]. We hypoth-
esize that these conformational changes, governed by
UBL-UBA interactions, are important for HHR23A func-
tion.
To determine how UBL and UBA domain interactions
contribute to Rad23/HHR23A function in ubiquitin-
mediated proteolysis, we identified mutations that dis-
rupt UBL-UBA binding, then tested the ability of the
mutant proteins to bind components of the ubiquitin-
proteasome pathway and to mediate delivery of a ubiqui-
tinated substrate to the proteasome. Our results show that
the interactions of the UBL and UBA domains with each
other and with other proteins are interdependent, and
that modulating proteasome-binding is important for the
role of Rad23/HHR23 in proteasomal targeting.
Results
Identification of UBL mutations that reduce UBA-binding
To identify UBL mutations that affect UBA-binding, we
established an affinity column chromatography assay
using resin-bound UBA domains and mobile ligands. To
demonstrate that our assay can distinguish proteins based
on their relative affinities for the UBA domains, control
experiments were performed with ubiquitin and SUMO.
Both proteins are similar in size and structure to the UBL
domain but ubiquitin binds the UBA domains whereas
SUMO does not [14,15,21]. Equal amounts of hemagglu-
tinin-tagged SUMO (HA-SUMO), polyhistidine-tagged
ubiquitin (Ub-His), and FLAG-tagged wild-type HHR23A
UBL (UBL-FLAG) were mixed and loaded onto the GST-
HHR23A~ΔUBL column. HA-SUMO eluted from the col-
umn first, followed by the wild-type UBL. Ub-His eluted
from the column only when the salt concentration in the
running buffer was increased from 150 mM to 400 mM
(Additional file 1A). Therefore, the order in which ubiqui-
tin, UBL and SUMO eluted from the GST-HHR23A~ΔUBL
column corresponded to their relative ability to interact
with UBA domains. To confirm that the difference in
retention time of each protein on the column is specifi-
cally due to their respective abilities to bind the UBA
domains, we conducted a similar control experiment
using a glutathione-sepharose column charged with GST
only. HA-SUMO, Ub-His and UBL-FLAG all eluted from
the GST column simultaneously (Additional file 1B).
To abrogate UBL-UBA binding, we mutated residues
located on the UBA-binding surface of HHR23A [18] that
are conserved in the other human homolog of Rad23,
HHR23B. We also considered data from previous struc-
tural studies of HHR23A, which showed that UBL-UBA
binding is mediated mainly by hydrophobic interactions
and that specificity is conferred by the topology of the
binding surfaces [18,22]. The UBA-binding surface of the
UBL domain is predominantly hydrophobic with a few
basic regions [23] whereas the UBL-binding surface of the
UBA domains are similarly hydrophobic but with a few
acidic residues [20]. Glutamic acid mutations in the UBA-
binding surface would cause electrostatic repulsion
against the UBA domains and thus be effective at disrupt-
ing the UBL-UBA interaction. Therefore, we mutated L10,
K47 and T77 of HHR23A to glutamic acid, individually or
in combination (as indicated in Figure 1A).
To determine the affinity of these UBL mutants for UBA
domains relative to wild-type UBL, UBL domain con-
structs were mutated accordingly and tested in our affinity
column chromatography assay. As shown in Figure 1C,
wild-type UBL began eluting off the column in fractions
18–20 and the elution profile of the K47A UBL mutant is
identical to that of the wild-type UBL domain. In contrast,
the L10E/K47E double mutant began to elute in fraction
12 and the K47/T77E and K47E mutants in fraction 14.
These data indicate that the glutamic acid UBL mutants,
but not the alanine mutant, have a reduced ability to bind
the UBA domains relative to the wild-type UBL.BMC Biochemistry 2008, 9:4 http://www.biomedcentral.com/1471-2091/9/4
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HHR23A bearing UBA-binding mutations in the UBL 
domain show enhanced binding to polyubiquitin
The ubiquitin-binding surface on the UBA domains over-
laps significantly with that involved in binding the UBL
domain [19,20]. Disrupting the intramolecular UBL-UBA
domain interactions is expected to make the UBA
domains more accessible to ubiquitin. We probed the
affinity of mutant HHR23A protein for ubiquitin binding
by assessing the extent to which each competed with
resin-bound GST-HHR23A for polyubiquitin-binding. As
shown in Figure 2A, polyubiquitin bound GST-HHR23A
but not GST alone. As increasing amounts of untagged
wild-type HHR23A was used as a competitor, the amount
of polyubiquitin bound to GST-HHR23A decreased. As
expected, HHR23A~ΔUBL competed with GST-HHR23A
more effectively than wild-type HHR23A for polyubiqui-
tin-binding whereas the HHR23A L198A/L355A double
mutant, in which the UBA domains are unfolded and thus
unable to bind ubiquitin [14,20], did not compete at all.
The HHR23A UBL mutants were then tested as competi-
tors in the GST-pulldown competition assay. All the
bands in the polyubiquitin Western blot are conjugates of
free ubiquitin, but rather than quantify a smear, we quan-
tified the specific band corresponding to tetra-ubiquitin,
which is the minimum length required for proteasomal
targeting [24]. The amount of tetra-ubiquitin bound to
GST-HHR23A in the presence of competitor was then
Glutamic acid mutations in the UBL domain reduce binding to the UBA domains Figure 1
Glutamic acid mutations in the UBL domain reduce binding to the UBA domains. (A) The electrostatic potential is 
mapped onto the surface diagram of the UBL domain of HHR23A. Positive and negative charges are indicated by blue and red 
respectively. GRASP was used to generate the surface diagram, using the parameters -25.4 to -12.7 and 25.4 to 12.7 kT to gen-
erate the surface potentials. (B) The ribbon diagram of the UBL domain of HHR23A was generated with MOLMOL [37], using 
reported UBL domain coordinates for HHR23A. (C) Equal amounts of wild-type UBL-His and mutated UBL-FLAG were 
loaded onto a GST-HHR23A~ΔUBL column. The column was developed with PBS and fractions were collected for analysis by 
Western blotting, using antibodies against each epitope tag. Visualization of the proteins was performed with LI-COR's Odys-
sey Imaging System.
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expressed as a percentage of the amount of tetra-ubiquitin
bound in the absence of competitor (Figure 2B). When
wild-type HHR23A was used as a competitor, the amount
of polyubiquitin bound to GST-HHR23A decreased from
87% to 39% as the ratio of competitor to GST-HHR23A
was increased from 0.2 to 1. As expected, HHR23A~ΔUBL
was a more effective competitor than wild-type HHR23A,
with only 75% of ubiquitin bound at a competitor to GST-
HHR23A ratio of 0.2, and only 29% bound at a ratio of 1.
This result is consistent with previous findings that
HHR23A lacking the UBL domain exhibits higher affinity
for polyubiquitin chains compared to the full-length pro-
tein [25].
In contrast, the UBA domain double mutant L198A/
L355A did not compete with GST-HHR23A for polyubiq-
uitin binding. The UBL domain mutants L10E/K47E and
K47E/T77E, which showed reduced UBA-binding (Figure
1C), competed for ubiquitin-binding more effectively
than wild-type HHR23A, and to a similar extent as
HHR23A~ΔUBL. Our results demonstrate that UBL-UBA
domain interactions reduce HHR23A's ability to bind
ubiquitin. They also provide evidence that the enhanced
polyubiquitin-binding of HHR23A~ΔUBL relative to
wild-type HHR23A is due to loss of auto-inhibition medi-
ated by UBL-UBA domain interactions.
HHR23A mutations that disrupt the UBL-UBA interaction enhance ubiquitin-binding Figure 2
HHR23A mutations that disrupt the UBL-UBA interaction enhance ubiquitin-binding. (A) GST-HHR23A, 
untagged mutant HHR23A, free polyubiquitin chains, and glutathione-sepharose beads were mixed together. After the resin 
was washed, the bound proteins were eluted and resolved by SDS-PAGE and Western blotting performed with an antibody 
against polyubiquitin. While all the bands are conjugates of free ubiquitin, the arrow indicates that which corresponds to 
tetraubiquitin. (B) The band corresponding to tetraubiquitin was quantified with a Biorad Fluor-S Max phosphoimager and data 
from a representative experiment are presented here.
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UBA-binding mutations in the Rad23 UBL domain impair 
proteasome-binding
In addition to regulating ubiquitin-binding, UBL-UBA
domain interactions could also affect proteasome-bind-
ing such that it is enhanced when the HHR23 proteins are
bound to ubiquitinated proteins. For this hypothesis to be
true, the proteasome must bind a surface on the UBL
domain overlapping with that which binds the UBA
domains. Indeed, the UBL domain is necessary and suffi-
cient for interaction with the proteasome [11] and the
binding of HHR23A to S5a disrupts UBL-UBA domain
binding [18]. Therefore, we tested whether the UBA-bind-
ing surface of HHR23 family proteins is required for pro-
teasome interaction.
Just as ubiquitin itself binds multiple subunits of the pro-
teasome, including Rpn10/S5a and Rpt6/S6' [26,27], so
could the Rad23/HHR23 proteins. Therefore, we tested
the ability of our UBL mutants, which are defective in
UBA-binding, to interact with purified proteasomes
instead of with specific subunits. We also used the bud-
ding yeast Saccharomyces cerevisiae as a model system as it
is better-characterized and easier to manipulate geneti-
cally.
L10, K47 and T77 in HHR23A correspond to F9, K43 and
S73 in Rad23 respectively, as determined by sequence
alignment. We mutated these Rad23 residues to glutamic
acid as we had done for HHR23A. To test proteasome-
binding, we used recombinant, purified 32P-labelled
Rad23 proteins and purified yeast proteasomes in a elec-
trophoretic mobility shift assay. In the presence of protea-
somes, the mobility of wild-type Rad23, but not
Rad23~ΔUBL, decreased, as indicated by the arrowheads
in Figure 3. The intensity of the shifted band is an indica-
tor of the amount of proteasome-bound Rad23, which
increased as more proteasome was titrated into the reac-
tion. With the exception of the S73E mutant, the Rad23
UBL mutants showed no detectable interaction with the
proteasome in vitro. This finding provides strong evidence
that Rad23 binds the proteasome via the same surface that
is responsible for S5a- and UBA-binding in HHR23A.
Rad23 UBL mutants show no detectable interaction with the proteasome in vitro Figure 3
Rad23 UBL mutants show no detectable interaction with the proteasome in vitro. All Rad23 constructs were bac-
terially expressed, purified and radiolabelled with [γ-32P]ATP in vitro via an N-terminal HMK site. After quantification by scintil-
lation counting and by Bradford assay, the radiolabelled proteins were normalized by counts and mixed with purified yeast 
proteasomes in a 1:10, 1:20 and 1:50 molar excess of proteasome over proteins. After incubation at 30°C for 15 minutes, the 
mixtures were electrophoresed on a 3.5% native gel at 100 V for 5 hours at 4°C. The arrows indicate free Rad23 proteins and 
the triangles indicate bands corresponding to proteasome-bound Rad23 proteins. "I/P" denotes the lane containing the input 
radiolabelled protein without any proteasome.
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Mutation of the Rad23 UBL domain impairs interactions 
with Ufd2
In addition to the proteasome, the Rad23/HHR23A UBL
domain binds other proteins involved in ubiquitin-medi-
ated degradation, including the ubiquitin ligase Ufd2
[6,28]. We thus tested whether our UBL mutants retain
their ability to interact with Ufd2. We used bacterially
expressed and purified GST-Ufd2 and Rad23 proteins in
GST-pulldown experiments, following which the bound
Rad23 proteins were detected by Western blotting for
Rad23. As expected, wild-type Rad23 bound to GST-Ufd2
but not to GST alone, whereas Rad23ΔUBL did not bind
to GST-Ufd2 (Figure 4). Interestingly, Ufd2-binding was
significantly reduced by the mutation of F9, but not of
K43 or of S73. This finding suggests that hydrophobic
interactions govern Ufd2 binding to Rad23, and that the
surfaces of Rad23 bound by Ufd2 and the proteasome do
indeed overlap partially.
UBA-binding mutations in the Rad23 UBL domain impair 
recruitment of a model substrate to the proteasome
The degradation of ubiquitinated substrates by proteas-
omes is tightly coupled to their deubiquitination by the
metalloisopeptidase activity of the Rpn11 subunit
[29,30]. The deubiquitinating activity of Rpn11 can be
unmasked in vitro in the presence of a 20S proteolytic
inhibitor such as epoxomicin, and can be used as a func-
tional readout for recruitment of model ubiquitinated
substrates to purified 26S proteasomes [31]. Therefore, we
used the CDK inhibitor Sic1 as a substrate in an in vitro
deubiquitination assay to determine the ability of each
Rad23 UBL mutant to target ubiquitinated substrates to
the proteasome.
In this assay, ubiquitinated MbpSic1 is prepared with SCF
complex (Figure 5 lane 1, which represents 100% pre-
formed ubiquitinated substrate). Upon the addition of
Rad23-deficient purified proteasomes, the ubiquitinated
MbpSic1 is targeted to the proteasome and deubiquiti-
nated. Prior treatment of the proteasomes with epox-
omicin inhibits substrate degradation and the extent to
which deubiquitination occurs may be assessed by West-
ern blotting for Sic1.
As shown in Figure 5, the proteasome exhibited basal deu-
biquitinating activity in the absence of wild-type Rad23.
Sic1 deubiquitination increased in the presence of wild-
type Rad23 (lanes 3 and 4), most likely due to the ability
of Rad23 to facilitate delivery of ubiquitinated Sic1 to the
proteasome. Sic1 deubiquitination was blocked by
Rad23~ΔUBL (lane 5) and limited to the basal level in the
presence of the F9E/K43E mutant, which showed no
detectable binding to the proteasome (Figure 3). In con-
trast, Sic1 deubiquitination was enhanced by the S73E
mutant, which retained proteasome-binding (Figure 3).
These results directly correlate deubiquitination with the
ability of Rad23 to deliver ubiquitinated substrates to the
proteasome.
Discussion
Interactions involving UBL and UBA domains are crucial
to the function of the Rad23 family of proteins in ubiqui-
tin-mediated protein degradation. In HHR23A, the
intramolecular binding between the UBL and UBA
domains is affected by and regulates interaction with
Mutation of the Rad23 UBL domain impairs proteasomal tar- geting Figure 5
Mutation of the Rad23 UBL domain impairs proteas-
omal targeting. Recombinant Sic1 was ubiquitinated in 
vitro, proteasomes lacking Rad23 were treated with epoxo-
mycin, and the two were then incubated at 30°C in the 
absence or presence of purified Rad23 proteins for 45 min-
utes. Deubiquitination of Sic1 was then analyzed by Western 
blotting for Sic1.
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other proteins [18]. We show that disruption of the
intramolecular UBL-UBA binding facilitates HHR23A
interaction with polyubiquitin. Our data support the
model that binding to either proteasomes or polyubiqui-
tin disrupts the UBL-UBA interaction, causing HHR23A to
adopt an open conformation that facilitates its interaction
with polyubiquitinated proteins or proteasomes respec-
tively. This coupling of proteasome-binding and sub-
strate-binding renders the Rad23 family more efficient in
docking ubiquitinated substrates with the proteasome.
Indeed, ubiquitin chains have been shown to enhance
Rad23 binding to the proteasome in vivo [32]. Also, UBL-
UBA domain interactions may enhance specificity by
blocking interactions that are weaker than the intramo-
lecular UBL-UBA interaction.
The UBA-binding surface of the Rad23/HHR23A UBL
domain also mediates binding to the proteasomal subunit
S5a as well as to other proteins such as the ubiquitin ligase
Ufd2. We had targeted residues on the edge of the UBA-
binding surface in an attempt to minimize disrupting
other interactions but our mutations also affected protea-
some-binding and Ufd2-binding. Our results are consist-
ent with a previous report suggesting that the binding
surfaces on the UBL domain for Ufd2 and the proteasome
may overlap [28]. The difficulty of specifically disrupting
interaction with only one protein without affecting others
suggests that these different binding surfaces overlap sig-
nificantly on the UBL domain and that the various inter-
actions may regulate one another. The use of the same
surface on Rad23/HHR23A for both proteasome- and
Ufd2-binding is consistent with a model in which Rad23
first binds ubiquitin conjugates associated with Ufd2,
then dissociates from Ufd2 and binds the proteasome, to
which the ubiquitin conjugates are thus delivered. This
model contrasts with one in which Rad23 bridges Ufd2
and the proteasome by binding them simultaneously.
The UBL mutants tested constitute an allelic series, with
the S73E mutant behaving most similarly to the wild-type
UBL, following by K43E and then F9E. Despite the lack of
detectable proteasome-binding in the native gel assay,
which is based on fractionation of the interacting species,
the UBL mutants possess sufficient residual affinity that
they can still interact functionally with proteasomes, as
evidenced by the deubiquitination of Sic1. Rad23ΔUBL
does not interact with proteasomes, yet it inhibited deu-
biquitination of Sic1. This dominant negative effect arises
from a sequestering mechanism, as Rad23ΔUBL can still
bind ubiquitin chains and thus interfere with recognition
by intrinsic ubiquitin receptors and other shuttling fac-
tors. In contrast, Sic1 was deubiquitinated in the presence
of the UBL mutants in a manner that is consistent with
each mutant's relative ability to bind proteasomes. These
data indicate that the capacity of Rad23 to bind proteas-
omes is essential for the ability of Rad23 family proteins
to target ubiquitinated substrates to the proteasome. This
model contrasts one in which ubiquitin chains bind the
proteasome directly.
Interestingly, HHR23A does not dimerize [18] whereas
Rad23 does so in a manner that involves the C-terminal
UBA domain [33,34]. Rad23 can also heterodimerize with
other UBL-UBA proteins such as Ddi1 [33,34] while
HHR23A interacts with hPLIC2 [35]. Therefore, intermo-
lecular UBL-UBA domain interactions may also play a reg-
ulatory role in the recruitment of ubiquitinated substrates
to the proteasome.
Conclusion
In conclusion, both the intramolecular as well as intermo-
lecular interactions of the UBL and UBA domains are
important for the function of Rad23 family proteins in the
ubiquitin-proteasome pathway. In this study we have
shown that physical interactions between the UBL and
UBA domains couple proteasome binding via the UBL
domain with ubiquitin-binding via the UBA domain, thus
priming Rad23/HHR23A for its role in shuttling ubiquiti-
nated substrates to the proteasome.
Methods
Plasmids
For bacterial expression, proteins were cloned into either
pGEX-6p-1 (Pharmacia) or pET-23a (Novagen). Where
applicable, the FLAG tag was inserted by QuikChange-XL
mutagenesis (Stratagene). We used pGEX2TK-based plas-
mids to express Rad23 and Rad23ΔUBL proteins for radi-
olabelling [7]. HHR23A (GenBank:P54725), HHR23A
UBL mutants, HHR23B (GenBank:P54727), and Rad23
(GenBank:P32628) UBL mutants were cloned into
"pGEX-6pK," in which the heart muscle kinase recogni-
tion site present in pGEX-2TK was inserted upstream of
the pGEX-6p-1 multiple cloning site by QuikChange-XL
mutagenesis (Stratagene). The GST-Ufd2-myc plasmid
has been previously described [28].
Protein expression and purification
Protein expression was induced in BL21(DE3) bacteria
with 0.4 mM isopropyl β-D-thiogalactoside (IPTG) for 4
hours at 37°C. For GST-fusion protein purification, bacte-
ria were lysed by sonication in PBS containing 2 mM DTT,
protease inhibitor cocktail (Roche), and 1% Triton X-100.
The proteins were purified on glutathione-sepharose
beads and either eluted with 10 mM reduced glutathione
in 50 mM Tris-HCl pH 8.0 or cleaved from the resin-
bound GST with PreScission protease (pGEX-6p1 pro-
teins) or thrombin (pGEX-2TK proteins) according to the
manufacturer's instructions. For the purification of poly-
histidine-tagged proteins, the bacteria were lysed in 25
mM sodium phosphate pH 8, 300 mM NaCl, 10 mM imi-BMC Biochemistry 2008, 9:4 http://www.biomedcentral.com/1471-2091/9/4
Page 8 of 10
(page number not for citation purposes)
dazole, 2 mM DTT and protease inhibitor cocktail
(Roche). The polyhistidine-tagged proteins were bound to
Ni-NTA resin (QIAGEN), washed with 50 mM sodium
phosphate pH 6.0, 300 mM NaCl and 20 mM imidazole.
The proteins were then eluted with 25 mM Tris-HCl pH 8,
300 mM NaCl, 2 mM DTT and 0.25 M imidazole. Purified
proteins were dialyzed overnight against PBS, 10% glyc-
erol and 2 mM DTT. Protein purity was verified by SDS-
PAGE analysis and Coomassie Blue staining.
Free polyubiquitin chains were synthesized in vitro by
incubating 100 nM E1 (Boston Biochem), 10 μM E2-25K
(Boston Biochem), and 40 μg ubiquitin (Sigma) with 25
mM Tris-HCl pH 7.6, 50 mM NaCl, 0.1 mM DTT, 5 mM
MgCl2, 4 mM ATP (Sigma), 0.03 mg/ml creatine kinase, 5
mM creatine phosphate, and 0.3 unit/ml pyrophos-
phatase, at 30°C for 2 hours.
Affinity column chromatography
Glutathione sepharose was saturated with purified GST-
HHR23A~ΔUBL. The charged resin was then loaded into
a 10 ml HR10/10 (Pharmacia) column. 1 μg each of wild-
type UBL-His and mutated UBL-FLAG were mixed and
loaded onto the GST-HHR23A~ΔUBL column, following
which the column was developed in PBS. 0.5 ml fractions
were collected, resolved by SDS-PAGE and the proteins
were detected by Western blotting. Antibodies used
included anti-FLAG M2 monoclonal antibody (Sigma),
anti-HA 12CA5 monoclonal antibody (produced in our
lab), and anti-polyhistidine affinity-purified rabbit poly-
clonal antibody (Rockland). Use of the Odyssey Imaging
System (LI-COR Biotechnology) enabled each protein to
be visualized simultaneously but distinctly.
Competition assay to assess polyubiquitin-binding
GST-HHR23A, untagged mutant variants of GST-
HHR23A, free polyubiquitin chains and glutathione-
sepharose beads were mixed for 1–2 hours at 4°C in bind-
ing buffer (20 mM Tris-HCl pH 7.2, 150 mM NaCl, 2 mM
EDTA, 2% (v/v) glycerol, 1 mM DTT) [14] supplemented
with 1% BSA. The resin was washed with binding buffer
supplemented with 0.5% NP40. Proteins were eluted
from the glutathione-sepharose resin and analyzed by
Western blotting for polyubiquitin (FK2 monoclonal
antibody, Affiniti Research Products). The band corre-
sponding to tetra-ubiquitin was quantified with a Biorad
Fluor-S Max phosphoimager. Total binding was defined
as the amount of polyubiquitin bound to the GST-
HHR23A in the absence of competitor.
Native gel assays for proteasome-binding
Proteasomes were purified from S. cerevisiae as previously
described [7]. All Rad23/HHR23 proteins were bacterially
expressed, purified on glutathione-sepharose beads, and
labelled in vitro with [γ-32P]ATP (NEN) and heart muscle
kinase according to the manufacturer's instructions (Phar-
macia Biotech). The radiolabelled proteins were cleaved
from the resin with thrombin or PreScission protease,
then quantified by scintillation counting and by Bradford
assay. The specific activities of the proteins were normal-
ized and mixed with proteasomes in a 1:50, 1:20, and
1:10 molar excess of proteasome over proteins. After incu-
bation at 30°C for 15 minutes, the mixtures were resolved
by 3.5% native PAGE essentially as previously described
[7,36], though electrophoresis was carried out for 5 hours
and the proteins visualized by autoradiography.
GST-pulldown assay for Ufd2-binding
Glutathione sepharose was saturated with purified GST-
Ufd2. Purified Rad23 proteins were then added together
with 50 mM HEPES pH 7.5, 150 mM NaCl, 5 mM EDTA,
2% Triton X-100, 0.2 mg/ml BSA, and protease inhibitor
cocktail (Roche). After mixing at 4°C for 60 minutes, the
resin was washed with PBS and 0.1% Tween-20. The resin-
bound Rad23 proteins were detected by Western blotting
using an antibody against Rad23 (a gift from Kiran
Madura).
In vitro deubiquitination assay
The in vitro deubiquitination assay was performed as pre-
viously described [5]. Essentially, proteasomes were puri-
fied from Rad23-deficient S. cerevisiae and preincubated
with 100 μM epoxomicin for 45 minutes at 30°C to
inhibit the protease activity of the proteasome. Ubiquiti-
nated MbpSic1 was then added to the proteasome and its
deubiquitination was analyzed by Western blotting for
Sic1. Rad23 was added to the deubiquitination assay
where indicated.
Abbreviations
UBL, ubiquitin-like; UBA, ubiquitin-associated; His, poly-
histidine; Ub, ubiquitin; HHR23, Human Homolog of
Rad23; S. cerevisiae, Saccharomyces cerevisiae.
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Retention of proteins on the GST-HHR23A~ΔUBL column corre-
sponds to their ability to interact with UBA domains. (A) Purified 
GST-HHR23A~ΔUBL protein was used to saturate glutathione-sepharose 
resin, which was in turn used to pack an HR10/10 column. Equal 
amounts of HA-tagged SUMO (HA-SUMO), polyhistidine-tagged ubiq-
uitin (Ub-His) and FLAG-tagged UBL (UBL-FLAG) were loaded simul-
taneously onto the column and the column was resolved in PBS. Fractions 
were collected and analyzed by Western blotting using epitope-specific 
antibodies. (B) Purified GST was bound to glutathione-sepharose resin in 
excess, which was then used to pack an HR10/10 column. Equal amounts 
of HA-SUMO, Ub-His and UBL-FLAG were mixed, loaded onto the col-
umn and analyzed as described above.
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